Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited develops epigenetics-based diagnostics through its Nucleosomics platform, which measures nucleosomes in blood and other bodily fluids. The company’s Nu.Q® product portfolio spans human diagnostics and monitoring for cancer, sepsis, trauma biomarker research and other disease areas, as well as veterinary oncology through Nu.Q® Vet assays.
VNRX news covers clinical publications and assay-development milestones, commercialization of Nu.Q® tests, veterinary cancer-test development, recombinant nucleosome products under rNuQ™, licensing and distribution activity, financial results, non-dilutive funding, equity financing and NYSE American listing-compliance matters. Volition’s research and development activities are centered in Belgium, with additional operations in the United States and London.
VolitionRx Limited (NYSE AMERICAN: VNRX) has been invited to join a government-backed study in France to assess blood biomarkers for early lung cancer detection, partnering with Hospices Civils de Lyon. The ILYAD study aims to evaluate Volition's Nu.Q® test in detecting lung cancer, involving over 400 subjects over the next year. Chief Commercial Officer Gael Forterre emphasized the critical need for effective lung cancer screening globally. Volition specializes in developing cost-effective blood tests using its innovative Nucleosomics™ technology.
VolitionRx Limited (NYSE AMERICAN: VNRX) has launched its Nu.Q® Vet Cancer Screening Test across the U.S. and plans to expand into Europe via Heska Corporation (NASDAQ: HSKA). The test offers an accurate, affordable, and non-invasive method for early cancer detection in dogs. With approximately 84 million pet dogs in the U.S., this screening can enhance health outcomes by facilitating early treatment. This partnership aligns with Heska's growth strategy in advanced veterinary diagnostics, following a $28 million licensing agreement with Volition.
VolitionRx Limited (NYSE AMERICAN: VNRX) has signed a global supply agreement with a leading pet healthcare provider to supply the Nu.Q® Vet Cancer Test via its laboratory network. This test aims at early cancer detection in pets, particularly senior dogs, providing significant market potential given the 84 million pet dogs in the U.S. Dr. Tom Butera emphasized that this agreement helps commercialize their technology in animal healthcare. Clinical studies indicate the test can detect 76% of systemic cancers with high specificity.
Xenetic Biosciences (NASDAQ: XBIO) announced the signing of a patent assignment from CLS Therapeutics as part of a collaboration with CLS and VolitionRx (NYSE AMERICAN: VNRX) to develop NETs-targeted adoptive cell therapies for cancer. In exchange for the patent, Xenetic will issue 850,000 shares to CLS. This collaboration aims to combine Volition's Nu.Q technology and Xenetic's DNase-Armored CAR T platform, targeting various solid tumors where current therapies are ineffective. The partnership will also share proceeds from any resulting commercial products.
VolitionRx Limited (NYSE: VNRX) appointed Mickie Henshall to its board of directors effective August 15, 2022. Henshall brings over 20 years of marketing experience in the IVD and life science industries, previously holding key positions at Illumina and REALM IDx. The board believes her expertise will support Volition's commercialization efforts, particularly regarding its Nu.Q® technology. Henshall noted the company's potential to revolutionize diagnostics for life-altering diseases. Volition is focused on developing cost-effective blood tests for monitoring diseases, including cancer.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced its second-quarter financial results for the period ending June 30, 2022. The company reported cash and cash equivalents of approximately $16.7 million, down from $20.6 million at year-end 2021. However, they secured $6.4 million via a public offering post-quarter and received $1.5 million in non-dilutive funding. Volition has made strides with the CE Mark for its Nu.Q® NETs test in Europe and is expanding clinical studies in the U.S. with MD Anderson and Diagnostic Oncology CRO LLC, aiming for FDA clearance in 2023.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center to study neutrophil extracellular traps (NETs) in cancer patients with sepsis. Led by Professor Jyotika Sharma, the study will utilize Volition's Nu.Q® NETs test, recently CE marked for NETosis evaluation. This research targets the critical early identification of sepsis risk in cancer patients, aiming to improve outcomes. High NET levels are linked to severe reactions and organ failure, emphasizing the test's potential in clinical settings.
VolitionRx Limited (NYSE AMERICAN: VNRX) has appointed Diagnostic Oncology CRO, LLC (DXOCRO) to lead development and clinical validation studies for its Nu.Q® product range in the U.S. The collaboration aims to establish clinical utility for its tests related to sepsis and cancer, ultimately seeking FDA clearance. DXOCRO brings expertise in commercialization and regulatory affairs to Volition, enhancing its strategy for U.S. market entry. This partnership supports Volition's objective to demonstrate the potential of its Nucleosomics™ technology in improving patient outcomes.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced a $1.5 million non-dilutive funding from Namur Invest Capital Risk in Belgium. This funding will support an early access program for Volition's Nu.Q® product portfolio across the EU, UK, and USA. COO Gaetan Michel expressed excitement for advancing Nucleosomics™ technology and engaging industry leaders. The funding is part of over $14 million in grants from Walloon Region since 2016, and the loan will bear a 6% interest rate, repayable over four years, maturing on July 31, 2026.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced the closing of its public offering of 3,450,000 shares at $2.00 each, raising gross proceeds of $6.9 million. The proceeds will be allocated for research, product development, clinical studies, and potential strategic acquisitions. The offering was facilitated by Newbridge Securities Corporation and is part of a previously filed shelf registration. The company focuses on developing blood tests to diagnose serious diseases using its Nucleosomics™ platform.